Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPOWER-CSCC-1: Cemiplimab in advanced CSCC
NCT02760498Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2016
- Primary completion
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 8
01
Overview
A Phase 2 trial of cemiplimab in cutaneous squamous cell carcinoma (cSCC), sponsored by Regeneron Pharmaceuticals. Started Apr 2016; status: completed.
02
Drugs
cemiplimab
03
Conditions
cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT02760498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02760498.